Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | NCF1 | P14598 | 4/20 | 0.56 |
| ▸ | ACP1 | P24666 | 2/20 | 0.51 |
| ▸ | TERT | O14746 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790530 | 0.85 | CYP1A2 (0.56) | CYP1A2NCF1KDM4EUSP2ALDH1A1 | |
| SCHEMBL30367038 | 0.83 | CYP1A2 (0.50) | CYP1A2NCF1KDM1AKDM4EALDH1A1 | |
| SCHEMBL30367104 | 0.80 | CYP1A2 (0.50) | CYP1A2NCF1KDM1A | |
| SCHEMBL29419409 | 0.79 | ACP1 (0.50) | CYP1A2ACP1KDM1AKDM4EUSP2 | |
| SCHEMBL5431607 | 0.79 | ACP1 (0.50) | CYP1A2ACP1KDM1AKDM4EUSP2 | |
| SCHEMBL13701566 | 0.79 | LMNA (0.58) | CYP1A2TERTKDM1AKDM4EALDH1A1 | |
| SCHEMBL6458326 | 0.79 | BACE1 (0.59) | NCF1ACP1KDM1AKDM4EALDH1A1 | |
| SCHEMBL30367213 | 0.79 | CYP1A2 (0.49) | CYP1A2NCF1KDM1AKDM4EALDH1A1 | |
| SCHEMBL4863068 | 0.79 | NCF1 (0.50) | CYP1A2NCF1KDM4EALDH1A1MAPT | |
| SCHEMBL4073181 | 0.78 | TERT (0.55) | CYP1A2NCF1TERTADORA2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4087889-B1 | STABLE MASS POLYMERIZABLE POLYCYCLOOLEFIN COMPOSITIONS AS 3D PRINTING MATERIALS AND A METHOD OF FABRICATION THEREOF | PROMERUS LLC (US) | 2024-03-06 | — | — | EP | claimed |
| US-11697701-B2 | Stable mass polymerizable polycycloolefin compositions as 3D printing materials and a method of fabrication thereof | PROMERUS, LLC (US) | 2023-07-11 | — | — | US | claimed |
| US-11692056-B2 | Stable polycycloolefin polymer and inorganic nanoparticle compositions as optical materials | PROMERUS, LLC (US) | 2023-07-04 | — | — | US | claimed |
| EP-4087889-A1 | STABLE MASS POLYMERIZABLE POLYCYCLOOLEFIN COMPOSITIONS AS 3D PRINTING MATERIALS AND A METHOD OF FABRICATION THEREOF | Promerus, LLC (US) | 2022-11-16 | — | — | EP | claimed |
| US-11299573-B2 | Stable mass polymerizable polycycloolefin compositions as 3D printing materials and a method of fabrication thereof | PROMERUS LLC (US) | 2022-04-12 | — | — | US | claimed |
| US-20210221931-A1 | STABLE MASS POLYMERIZABLE POLYCYCLOOLEFIN COMPOSITIONS AS 3D PRINTING MATERIALS AND A METHOD OF FABRICATION THEREOF | PROMERUS, LLC (US) | 2021-07-22 | — | — | US | claimed |
| WO-2021142402-A1 | STABLE MASS POLYMERIZABLE POLYCYCLOOLEFIN COMPOSITIONS AS 3D PRINTING MATERIALS AND A METHOD OF FABRICATION THEREOF | PROMERUS, LLC (US) | 2021-07-15 | — | — | WO | claimed |
| WO-2021016503-A1 | STABLE POLYCYCLOOLEFIN POLYMER AND INORGANIC NANOPARTICLE COMPOSITIONS AS OPTICAL MATERIALS | PROMERUS, LLC (US) | 2021-01-28 | — | — | WO | claimed |
| US-20210024685-A1 | STABLE POLYCYCLOOLEFIN POLYMER AND INORGANIC NANOPARTICLE COMPOSITIONS AS OPTICAL MATERIALS | PROMERUS, LLC (US) | 2021-01-28 | — | — | US | claimed |
| US-12037431-B2 | Stable mass polymerizable polycycloolefin compositions as 3D printing materials and a method of fabrication thereof | PROMERUS, LLC (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4087889-B1 | STABLE MASS POLYMERIZABLE POLYCYCLOOLEFIN COMPOSITIONS AS 3D PRINTING MATERIALS AND A METHOD OF FABRICATION THEREOF | PROMERUS LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4288479-A1 | LONG SHELF LIFE STABLE PHOTOACTIVE MASS POLYMERIZABLE POLYCYCLOOLEFIN COMPOSITIONS AS OPTICAL MATERIALS | Promerus, LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11697701-B2 | Stable mass polymerizable polycycloolefin compositions as 3D printing materials and a method of fabrication thereof | PROMERUS, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-11692056-B2 | Stable polycycloolefin polymer and inorganic nanoparticle compositions as optical materials | PROMERUS, LLC (US) | 2023-07-04 | — | — | US | disclosed |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | AVENTIS PHARMA S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
| US-7482352-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2009-01-27 | — | — | US | disclosed |
| US-7482352-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2009-01-27 | — | — | US | disclosed |
| US-6825215-B2 | N-HYDROXY-2-(2-(((4-((2-METHYL-4-QUINOLINYL)METHOXY)PHENYL) -SULFONYL)METHYL)-2-PYRROLIDINYL)ACETAMIDE, FOR EXAMPLE AND OTHER QUINOLINE CONTAINING N-HYDROXYACETAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1355901-A2 | 1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASE AND TNF-$g(a) | Bristol-Myers Squibb Pharma Company (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002055516-A2 | 1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASE AND TNF-$g(a) | BRISTOL MYERS SQUIBB CO (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | DPYD, NTPCR, NME1 | CYP1A2 1561/4885NCF1 1011/4885ACP1 1582/4885 |
| US-11697701-B2 | Stable mass polymerizable polycycloolefin compositions as 3D printing materials and a method of fabrication thereof | RRP15, PPOX, NONO | CYP1A2 1047/4885NCF1 2660/4885ACP1 438/4885 |
| US-12037431-B2 | Stable mass polymerizable polycycloolefin compositions as 3D printing materials and a method of fabrication thereof | RRP15, PPOX, NONO | CYP1A2 1047/4885NCF1 2660/4885ACP1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.